Recombinant TNFSF11 (Denosumab Biosimilar) antibody

Catalog No. ABIN7200656

This Mouse Monoclonal antibody specifically detects TNFSF11 (Denosumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.

Quick Overview for Recombinant TNFSF11 (Denosumab Biosimilar) antibody (ABIN7200656)

Target: TNFSF11 (Denosumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TNFSF11 (Denosumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Product Details anti-TNFSF11 (Denosumab Biosimilar) Antibody

Purpose: Denosumab Biosimilar, Human RANKL Monoclonal Antibody

Specificity: The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein.

Characteristics: Recombinant Humanized IgG2 Monoclonal Antibody.

Purification: Protein A affinity column

Purity: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody denosumab biosimilar was produced in the denosumab biosimilar CHO stable cell line.

Isotype: IgG2 kappa

Application Details

Application Notes: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by denosumab.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Handling Advice: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Storage: -20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months

Target Details for TNFSF11 (Denosumab Biosimilar)

Target: TNFSF11 (Denosumab Biosimilar)

Target Type: Biosimilar

Background: Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.